Cancer Supportive Care Drugs Market Size & Share 2023 to 2032
Market Size by Drug Class (G-CSFs, ESAs, Anti-emetics, Bisphosphonates, Opioids, NSAIDs), Cancer type (Breast, Lung, Prostate, Colorectal, Melanoma), Distribution Channel (Hospital, Drug Store).
Report ID: GMI6489
|
Published Date: August 2023
|
Report Format: PDF
Download Free PDF
Authors:
Monali Tayade, Jignesh Rawal
Cancer Supportive Care Drugs Market Size
Cancer Supportive Care Drugs Market size was estimated to be USD 14.4 billion in 2022 and is predicted to increase at a growth rate of 1.9% till 2032. Progress in cancer treatments like chemotherapy, radiation therapy, targeted therapy, and immunotherapy has elevated treatment effectiveness. Prioritizing the well-being of cancer patients has gained significant prominence in cancer care.
Cancer Supportive Care Drugs Market Key Takeaways
Market Size & Growth
Key Market Drivers
Challenges
The rise in awareness and education, the aging demographic, the growing inclination towards personalized medicine, and the growing population of cancer survivors have collectively emphasized the management of long-term treatment-related effects.
Moreover, the increasing global incidence and prevalence of cancer contribute to a growing patient population that requires supportive care. According to American Cancer Society, Inc. over 1.9 million new cancer cases is expected to be diagnosed in the U.S. in 2023. As more individuals are diagnosed with cancer, the demand for effective supportive care drugs to manage treatment-related side effects also rises.
COVID-19 Impact Analysis
The COVID-19 pandemic had a significant impact on the healthcare industry, including the cancer supportive care drugs market. Throughout the pandemic, various healthcare systems faced challenges with cancer treatment due to financial reallocation, lockdowns, and concerns about virus transmission.
Furthermore, numerous clinical studies for cancer medications, including supportive care drugs, were halted or postponed during the pandemic to prioritize patient safety. This interruption had implications for the development and testing of new supportive care drugs.
Nonetheless, telemedicine and remote healthcare services gained prominence during the pandemic to ensure patient safety. While certain supportive care services could be delivered online, the absence of in-person care might have influenced the overall management of treatment-related symptoms.
Cancer Supportive Care Drugs Market Trends
Some key trends in the industry include a growing focus on personalized medicine in supportive care, the development of targeted therapies for specific side effects of cancer treatment, the integration of digital health technologies, including mobile apps and telemedicine platforms, into supportive care programs. Additionally, there is a growing emphasis on managing long-term treatment-related effects, an increasing use of combination therapies that include supportive care drugs alongside cancer treatments, and the development of biologic agents, such as monoclonal antibodies, to target specific pathways involved in treatment-related symptoms. These trends reflect efforts to enhance the overall quality of life for cancer patients by efficiently managing treatment-related symptoms and providing the most effective and comprehensive supportive care.
Cancer Supportive Care Drugs Market Analysis
Based on drug class, the cancer supportive care drugs market is segmented into G-CSFs (granulocyte-colony stimulating factors), ESAs (erythropoiesis stimulating agents), anti-emetics, bisphosphonates, opioids, NSAIDs, and other drug types. In 2022, the G-CSFs (granulocyte-colony stimulating factors) segment accounted for the largest share of 22.8% in the industry. The main purpose for using G-CSF is to avoid neutropenia. Chemotherapy commonly impacts rapidly dividing cells, such as neutrophils in bone marrow, resulting in decreased neutrophil numbers. G-CSFs stimulate the bone marrow to produce more neutrophils, lowering the risk of severe neutropenia and related infections. In addition, due to the increased risk of infection, neutropenia could result in chemotherapy dosage reductions, delays, or suspensions. Healthcare practitioners can follow the prescribed chemotherapy treatment to attain optimal treatment results by using G-CSFs to avoid neutropenia.
Based on cancer type, the cancer supportive care drugs market is segmented into breast cancer, lung cancer, melanoma, prostate cancer, colorectal cancer, liver cancer, stomach cancer, and other cancer types. The breast cancer segment held the significant industry share of around 14.1% in 2022. Breast cancer treatment often involves a combination of surgery, radiation therapy, chemotherapy, and targeted therapy. Each of these modalities can cause different side effects, such as pain, nausea, fatigue, and emotional distress. Supportive care drugs address these diverse symptoms to improve patients' overall well-being. According to National Breast Cancer Foundation, Inc. in the U.S., 1 out of 8 women will be diagnosed with breast cancer over her lifetime. An estimated 297,790 women and 2,800 men will be diagnosed with invasive breast cancer in 2023.
Based on distribution channel, the cancer supportive care drugs market is segmented as hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a dominant industry share of 58.9% in 2022 and is expected to grow at a CAGR of 2% by 2032. Hospital pharmacists have specialized knowledge in oncology and supportive care drugs. They collaborate with healthcare teams to ensure appropriate drug selection, dosing, and administration based on individual patient needs.
Asia Pacific cancer supportive care drugs market accounted for significant revenue in 2022 and is expected to reach USD 6.1 billion in 2032 with a CAGR of 2.3% from 2023-2032. The Asia Pacific region has witnessed a rising incidence of cancer, attributed to factors such as population growth, aging, changing lifestyles, and environmental factors. As cancer cases increase, so does the demand for supportive care drugs to manage treatment-related symptoms.
Moreover, many countries in the Asia Pacific are adopting Western-style cancer treatments, including chemotherapy and targeted therapies. These therapies often come with side effects that require effective supportive care interventions.
Cancer Supportive Care Drugs Market Share
Major industry players operating in the cancer supportive care drugs market include :
Cancer Supportive Care Drugs Market Industry News:
The cancer supportive care drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:
Click here to Buy Section of this Report
By drug class
By cancer type
By distribution channel
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →